Measurement of chemotherapy-induced alopecia-time to change

被引：8
作者：
van den Hurk, C. J. G. [1 ]
Winstanley, J. [2 ,3 ]
Young, A. [4 ]
Boyle, F. [2 ,3 ]
机构：
[1] Netherlands Comprehens Canc Org, Eindhoven, Netherlands
[2] Mater Hosp, Patricia Ritchie Ctr Canc Care & Res, Sydney, NSW, Australia
[3] Univ Sydney, Sydney, NSW 2006, Australia
[4] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England
来源：
SUPPORTIVE CARE IN CANCER | 2015年 / 23卷 / 05期
基金：
美国国家卫生研究院;
关键词：
Alopecia; Chemotherapy; Side effect; Data quality; METASTATIC BREAST-CANCER; RANDOMIZED PHASE-III; EPIRUBICIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; MULTICENTER; DOCETAXEL; IMPACT; FEC;
D O I：
10.1007/s00520-015-2647-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Data on chemotherapy-induced alopecia (CIA) as a side effect of cancer treatment are scarce. CIA is given minimal attention in clinical trials and in the literature. However, when asking the patients with cancer for their opinion, CIA appears to have a major impact, particularly on body image and quality of life. Currently, there is no commonly used measure to evaluate CIA; It is time to improve the management and measurement of CIA.
引用
收藏
页码：1197 / 1199
页数：3
相关论文
共 17 条
  • [1] [Anonymous], COMM TERM CRIT ADV E
  • [2] Breed WP, 2011, Expert Reviews Dermatology, V6, P109
  • [3] Doubling epirubicin dose intensity (100 mg/m(2) versus 50 mg/m(2)) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer
    Brufman, G
    Colajori, E
    Ghilezan, N
    Lassus, M
    Martoni, A
    Perevodchikova, N
    Tosello, C
    Viaro, D
    Zielinski, C
    Krainer, M
    Salzer, H
    Schuller, J
    Dittrich, C
    Scheithauer, W
    Zamagni, C
    Ambrosini, G
    Colucci, G
    Gentilini, P
    Zaniboni, A
    Pacini, P
    Bianco, R
    Mustacchi, G
    DAprile, M
    DeMatteis, A
    Oliveira, C
    Jordaan, J
    Gudgeon, A
    VanZyl, J
    Rakowsky, E
    Inbar, M
    Rath, P
    Cohen, Y
    Shani, A
    Fried, G
    Hegg, R
    Neto, AB
    Bader, G
    Braga, RF
    Vitoc, C
    Puerto, VML
    Valle, AE
    Salazar, JD
    Sanchez, JC
    Villela, GM
    Fountzilas, G
    [J]. ANNALS OF ONCOLOGY, 1997, 8 (02) : 155 - 162
  • [4] Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: Results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group
    Del Mastro, L
    Venturini, M
    Lionetto, R
    Carnino, F
    Guarneri, D
    Gallo, L
    Contu, A
    Pronzato, P
    Vesentini, L
    Bergaglio, M
    Comis, S
    Rosso, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) : 2213 - 2221
  • [5] Have men been overlooked? A comparison of young men and women's experiences of chemotherapy-induced alopecia
    Hilton, Shona
    Hunt, Kate
    Emslie, Carol
    Salinas, Maria
    Ziebland, Sue
    [J]. PSYCHO-ONCOLOGY, 2008, 17 (06) : 577 - 583
  • [6] Hurk van den CJG, 2013, THESIS LEIDEN U LEID
  • [7] Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
    Kluger, N.
    Jacot, W.
    Frouin, E.
    Rigau, V.
    Poujol, S.
    Dereure, O.
    Guillot, B.
    Romieu, G.
    Bessis, D.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (11) : 2879 - 2884
  • [8] Enhancing Therapeutic Decision Making When Options Abound: Toxicities Matter
    Kuderer, Nicole M.
    Wolff, Antonio C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (19) : 1990 - 1993
  • [9] The impact of cancer and chemotherapy: Perceptual similarities and differences between cancer patients, nurses and physicians
    Mulders, Marco
    Vingerhoets, Ad
    Breed, Wim
    [J]. EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2008, 12 (02) : 97 - 102
  • [10] Peerbooms M, 2015, ASIA PACIFI IN PRESS
12